CADTH has received notice of a pending submission from AstraZeneca for Forxiga (dapagliflozin propanediol monohydrate) for patients with type 2 diabetes mellitus. For information about the patient input process or for additional instructions, please see the patient input page of the CADTH website. Note that typically only patient groups may submit input; however, there is currently a pilot process for receiving patient input submissions from individual patients and caregivers.

For more details, go to: https://cadth.ca/cdr/patient-input/open-calls-for-patient-input/cdr-patient-input-submission?brand_name=Forxiga&generic_name=Dapagliflozin&indicator=Diabetes%20mellitus%20%28Type%202%29